Impact of Skeletal Muscle Depletion on Patients with Myelodysplastic Syndrome Treated with Azacitidine.

Eri TakadaNobuhiko NakamuraYuto KanedaKenji FukunoShin LeeKei FujitaTetsuji MorishitaYoshikazu IkomaTakuro MatsumotoHiroshi NakamuraJunichi KitagawaNobuhiro KanemuraSenji KasaharaTakeshi HaraHisashi TsurumiMasahito Shimizu

Published in: Hematology reports (2024)

Reduced skeletal muscle mass may predict severe hematological toxicity in MDS patients treated with AZA.

Keyphrases

skeletal muscle
acute myeloid leukemia
insulin resistance
early onset
oxidative stress
type diabetes
adipose tissue